Eligard receives marketing authorisation in Germany

Published: 2-Dec-2003

Atrix Laboratories has received marketing authorisation in Germany for its one-month prostate cancer product, Eligard 7.5mg (leuprolide acetate) for injectable suspension, known as Leuprogel, through its European licensee MediGene.


Atrix Laboratories has received marketing authorisation in Germany for its one-month prostate cancer product, Eligard 7.5mg (leuprolide acetate) for injectable suspension, known as Leuprogel, through its European licensee MediGene.

Leuprolide acetate is a lutenizing hormone releasing hormone (LHRH) agonist. Sustained levels of leuprolide acetate decrease testosterone levels to suppress tumour growth in patients with hormone-responsive prostate cancer. 'Germany is the largest market for LHRH therapies in Europe, so gaining German approval is a major advancement in globalising this product,' said David R. Bethune, Atrix's chairman and ceo.

Approvals in other European countries are expected as part of the mutual recognition process.

  

You may also like